Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederinvestor.bluebirdbio.com
bluebird bio, Inc. News Releases
Get the latest updates from bluebird bio, Inc. News Releases directly as they happen.
Follow now 41 followers
Latest posts
Last updated about 2 hours ago
Important Information for bluebird bio Stockholders to Tender Shares for Acquisition by Carlyle and SK Capital
about 2 hours ago
SOMERVILLE, Mass. --(BUSINESS WIRE)--May 9, 2025-- bluebird bio, Inc. (Nasdaq: BLUE) (“bluebird”)...
Carlyle and SK Capital Receive All Required Regulatory Approvals to Complete the Acquisition of bluebird bio
4 days ago
bluebird Board of Directors unanimously supports the transaction as the only viable...
bluebird bio confirms that Ayrmid, Ltd. has not delivered a binding offer or obtained necessary financing despite extensive engagement
23 days ago
bluebird Board reaffirms unanimous recommendation in support of transaction with Carlyle and...
bluebird bio Confirms Receipt of an Unsolicited Non-Binding Proposal from Ayrmid
about 1 month ago
SOMERVILLE, Mass. --(BUSINESS WIRE)--Mar. 28, 2025-- bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird”)...
bluebird bio Announces Definitive Agreement to be Acquired by Carlyle and SK Capital
3 months ago
bluebird stockholders to receive $3.00 per share in cash and a contingent...
bluebird bio Presents Positive Long-Term Data On LYFGENIA™ (lovotobegligene autotemcel) Gene Therapy for Sickle Cell Disease at 66th American Society of Hematology (ASH) Annual Meeting and Exposition
5 months ago
Stable production of anti-sickling adult hemoglobin (HBA T87Q ) and elimination or...
Long-Term Follow-Up Data Continue to Support Beti-Cel as a Potentially Curative Gene Therapy for β-Thalassemia Patients Who Require Regular Transfusions Through Achievement of Durable Transfusion Independence and Normal or Near-Normal Adult Hb Levels
5 months ago
Treatment effects sustained through long-term follow-up of beyond 10 years in the...
bluebird bio Announces 1-for-20 Reverse Stock Split
5 months ago
SOMERVILLE, Mass. --(BUSINESS WIRE)--Dec. 4, 2024-- bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird...
bluebird bio Confirms Participation in Center for Medicare and Medicaid Innovation (CMMI) Cell and Gene Therapy Access Model
5 months ago
Company and CMMI agreed to key terms to be offered to State...
bluebird bio Reports Third Quarter 2024 Results and Highlights Operational Progress and 2024 Guidance
6 months ago
- 74 patient starts completed or scheduled to date in 2024 across...
bluebird bio Adjourns Meeting of Stockholders and Announces Third Quarter Results Call
6 months ago
SOMERVILLE, Mass. --(BUSINESS WIRE)--Nov. 6, 2024-- bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird...
bluebird bio to Present Additional Long-Term Follow-up Data from Gene Therapy Programs in Sickle Cell Disease and Beta-Thalassemia at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition
6 months ago
SOMERVILLE, Mass. --(BUSINESS WIRE)--Nov. 5, 2024-- bluebird bio, Inc. (Nasdaq: BLUE) today...